Affilogic has designed Nanofitins® against 40+ targets to date, including a wide raNF-drug-conjugates-Imagenge of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (Virus-like Particles, bacteria, whole cells). The process can enable direct screening for inhibitors / competitors and is independent of the toxicity / immunogenicity of the target. Conversely, Nanofitins® can be tailored so as to bind that target without blocking its interaction with one natural ligand. They can thereby be designed as targeted inhibitors, or as vectors for specific transport.

In vivo neutralization

Usual systemic routes can be traveled by Nanofitins® aiming at neutralizing relevant interactions. Their naturally short half-life can be tuned thanks to proprietary albumin-binding technology.

There is more : intrinsic properties of Nanofitins® make them amenable to other routes, such as topical administration (skin and cornea), up to oral route. In vitro permeation assays have already demonstrated a high corneal penetration (Ussing chamber) and skin permeation (Frantz cell). We have already demonstrated in vivo efficacy in this approach of non-systemic targeted therapy in inflammatory skin diseases, and a European Consortium is at work for developing oral anti-TNFα Nanofitins®.

Read More

Want to know who are the Nanofitins® ?

Nanofitin-Drug-Conjugates

Nanofitins® can be easily conjugated to other moieties (small molecule, biologics, nanoparticles) by genetic fusion or click chemistry (regioselective conjugation). This means that the Nanofitins® can be considered not only as a neutralizing agent but also as a vector to increase target-specificity of a payload or enable BBB-crossing, intracellular targeting (PPI)…

Previous conjugation experiments with industrial partners include conjugation to enzymes for BBB-crossing, conjugation to toxins / loaded nanoparticles for cellular / intracellular targeting, conjugation to radioisotopes for in-vivo imaging…

Read More